Human Phenotyping Core
人类表型核心
基本信息
- 批准号:10016171
- 负责人:
- 金额:$ 36.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-07 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAutoantibodiesAutoimmune DiseasesBiological AssayBiological MarkersBlood CellsCaringCellsCharacteristicsClinicalCompetenceComplexConsultationsDataData AnalysesData SetDatabasesDevelopmentDiagnosticDiseaseEffectivenessEnsureEpigenetic ProcessEquipmentExperimental DesignsFlow CytometryFoundationsFreezingFundingFutureGenerationsGeneticGenetic PolymorphismGenomic DNAGenomicsGenotypeHumanHuman Herpesvirus 4Human ResourcesImmuneImmunologicsImmunophenotypingIndividualInflammatoryInvestigationKnowledgeMeasuresMediator of activation proteinMethodologyMethodsMolecularMolecular ProfilingOklahomaPathogenesisPathway interactionsPatientsPhenotypePlasmaPopulationPreparationProcessProteomicsQuality ControlReproducibilityResearchResearch PersonnelResourcesRheumatismSamplingSerumServicesSiteSpecimenStatistical ModelsSystemTechnical ExpertiseTechnologyTherapeuticTimeTransformed Cell LineVariantbasebiobankchemokineclinical centerclinical phenotypeclinically relevantcomputerized data processingcytokinedata qualitydesignexperienceexperimental studyhuman diseaseimmune functionmolecular phenotypenovelnovel strategiesphenotypic dataprecision medicineprognostic toolprogramsresponsesingle-cell RNA sequencingsuccesstranscriptometranscriptomics
项目摘要
Human Phenotyping Core Project Summary
The rapid development of new approaches to interrogate the immune and inflammatory systems comes
with a growing demand for both technical and conceptual expertise in these methodologies. The Human
Phenotyping Core was created to support these activities within the Oklahoma Rheumatic Disease Resources
Cores Center (ORDRCC). To address the most broadly scientifically interesting and clinically important
questions, our ORDRCC Investigators need access to cutting-edge approaches, such as scRNA-Seq/CITE-
Seq, ChipCytometry, and CyTOF to perform incisive experiments and to generate high-quality, reproducible
data. The Human Phenotyping Core will allow our investigators to ask novel questions regarding the molecular
phenotypes of rheumatic diseases. In addition to providing ORDRCC investigators with high-content
biomolecular phenotyping services, the Human Phenotyping Core in conjunction with the Clinical
Characterization and Biorepository Core (CCBC) will provide access to datasets containing previously
collected genetic, proteomic, and biomolecular phenotypes of clinical subjects whose samples are available
from the CCBC. The tight integration of the Human Phenotyping Core, CCBC and our databases will enable
investigators to efficiently phenotype samples and correlate molecular and cellular phenotypes with clinical
characteristics, to select more homogeneous patients for hypothesis-driven investigation and help provide the
foundational knowledge needed for precision medicine in rheumatic disease care.
By consolidating a range of technologies required for the complete characterization of molecular or
cellular phenotypes into a single unit, the Human Phenotyping Core (HPC) will streamline services to help
ORDRCC investigators in the efficient planning, design, execution and data analysis required for their
individual projects. The HPC will provide experience in performing research using clinical specimens,
technical expertise in a wide range of molecular and bioassays, access to equipment and resources thus
enabling cutting-edge approaches to address research questions, quality control assessment of the data
collected and data processing suitable for higher end statistical modeling of phenotype/clinical associations.
SPECIFIC AIM 1: Assist ORDRCC Investigators, JCIs and Scholars to navigate the stages of project
development, experimental design, resource planning and execution of translational and mechanistic studies
through Core Management and individual consultations.
SPECIFIC AIM 2: Provide access to advanced molecular phenotyping technologies and experienced
technical personnel for efficient execution of advanced experimental data plans.
SPECIFIC AIM 3: Establish processes to ensure data quality control, processing of raw data, and preparation
of data sets for more extensive analysis and statistical modeling.
SPECIFIC AIM 4: Evaluate, assess and implement new cutting-edge technologies for molecular phenotyping.
人类表型核心项目总结
询问免疫和炎症系统的新方法的迅速发展
对这些方法的技术和概念专业知识的需求日益增长。《人类》
表型核心是为了支持俄克拉荷马州风湿病资源中的这些活动而创建的
岩心中心(ORDRCC)。以解决最具科学意义和临床重要性的
问题,我们的ORDRCC调查人员需要使用尖端方法,如scRNA-Seq/Cite-
SEQ、芯片细胞术和CyTOF,以执行深入的实验并生成高质量、可重复性的
数据。人类表型核心将允许我们的研究人员提出关于分子的新问题
风湿性疾病的表型。除了为ORDRCC调查人员提供高内容
生物分子表型服务,人类表型核心与临床
特征和生物资源库核心(CCBC)将提供对包含以前
收集样本可用的临床受试者的遗传、蛋白质组和生物分子表型
来自CCBC。人类表型核心、CCBC和我们的数据库的紧密集成将使
研究人员高效地采集表型样本,并将分子和细胞表型与临床联系起来
特征,以选择更多同质性的患者进行假设驱动的研究,并帮助提供
风湿病护理中精准医学所需的基础知识。
通过整合完整表征分子或蛋白质的一系列技术
将细胞表型整合为一个单位,人类表型核心(HPC)将简化服务,以帮助
ORDRCC调查人员高效的规划、设计、执行和数据分析
个别项目。HPC将提供使用临床标本进行研究的经验,
在广泛的分子和生物分析方面的技术专长,从而获得设备和资源
采用前沿方法解决研究问题,对数据进行质量控制评估
适用于表型/临床关联的高端统计建模的收集和数据处理。
具体目标1:协助ORDRCC调查人员、JCI和学者浏览项目的各个阶段
翻译和机械研究的开发、实验设计、资源规划和执行
通过核心管理和个人协商。
具体目标2:提供先进的分子表型技术和经验
高效执行高级实验数据计划的技术人员。
具体目标3:建立流程以确保数据质量控制、原始数据处理和准备
用于更广泛的分析和统计建模的数据集。
具体目标4:评估、评估和实施新的前沿分子表型技术。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joel Marvin Guthridge其他文献
Joel Marvin Guthridge的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joel Marvin Guthridge', 18)}}的其他基金
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
新发自身免疫/纵向免疫系统分析(MONA-LISA)的机制
- 批准号:
10655219 - 财政年份:2023
- 资助金额:
$ 36.85万 - 项目类别:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core Admin Supplement: Preclinical Studies in Sjogren's
加速药物合作 - 自身免疫和免疫疾病组织研究核心管理补充:干燥病的临床前研究
- 批准号:
10834635 - 财政年份:2022
- 资助金额:
$ 36.85万 - 项目类别:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
加速药物合作——自身免疫和免疫疾病组织研究核心
- 批准号:
10687729 - 财政年份:2022
- 资助金额:
$ 36.85万 - 项目类别:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
加速药物合作——自身免疫和免疫疾病组织研究核心
- 批准号:
10452026 - 财政年份:2022
- 资助金额:
$ 36.85万 - 项目类别:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
加速药物合作——自身免疫和免疫疾病组织研究核心
- 批准号:
10596177 - 财政年份:2022
- 资助金额:
$ 36.85万 - 项目类别:
Ikaros family genes and lupus susceptibility across ethnically diverse populations
Ikaros 家族基因和不同种族人群的狼疮易感性
- 批准号:
9770772 - 财政年份:2018
- 资助金额:
$ 36.85万 - 项目类别:
Ikaros family genes and lupus susceptibility across ethnically diverse populations
Ikaros 家族基因和不同种族人群的狼疮易感性
- 批准号:
10238826 - 财政年份:2018
- 资助金额:
$ 36.85万 - 项目类别:
相似海外基金
Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
- 批准号:
EP/Y031091/1 - 财政年份:2024
- 资助金额:
$ 36.85万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 36.85万 - 项目类别:
Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 36.85万 - 项目类别:
Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
- 批准号:
10715807 - 财政年份:2023
- 资助金额:
$ 36.85万 - 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
- 批准号:
MR/Y003667/1 - 财政年份:2023
- 资助金额:
$ 36.85万 - 项目类别:
Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
- 批准号:
10740682 - 财政年份:2023
- 资助金额:
$ 36.85万 - 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
- 批准号:
487849 - 财政年份:2023
- 资助金额:
$ 36.85万 - 项目类别:
Operating Grants
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
- 批准号:
10481071 - 财政年份:2022
- 资助金额:
$ 36.85万 - 项目类别:
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
- 批准号:
10526475 - 财政年份:2022
- 资助金额:
$ 36.85万 - 项目类别: